Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation

Published 05/03/2024, 15:59
Updated 05/03/2024, 17:10
© Reuters.  Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation
EYEN
-

Benzinga - by Vandana Singh, Benzinga Editor.

Taiwan-based Formosa Pharmaceuticals and AimMax Therapeutics announced Monday that the FDA approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) for post-operative inflammation and pain following ocular surgery.

Utilizing a super potent corticosteroid, clobetasol propionate ophthalmic suspension 0.05% is derived from Formosa Pharma’s proprietary APNT nanoparticle formulation platform.

The formulation represents the first FDA-approved ophthalmic clobetasol propionate product and the first new steroid in over 15 years on the ophthalmic market, offering patients a convenient and straightforward dosing regimen (twice daily for 14 days without tapering).

Two Phase 3 trials demonstrated rapid and sustained clearance of inflammation and pain relief that was statistically and clinically superior to its matching placebo.

This eyedrop enters a $1.3 billion market for topical ophthalmic steroids and steroid combinations, driven by an estimated seven million ocular surgeries performed annually in the United States.

Eyenovia Inc (NASDAQ:EYEN) is Formosa Pharmaceuticals’ U.S. commercialization partner.

In August 2023, Formosa Pharmaceuticals partnered with Eyenovia, where by Eyenovia obtained exclusive U.S. rights for commercializing APP13007 for inflammation and pain following ocular surgery, $86 million, including upfront payment and milestones, with additional considerations throughout the agreement terms.

William Blair says that although clinical studies on APP13007 were conducted in patients after cataract surgery, its approved indication extends beyond post-cataract surgery.

The approval covers post-operative inflammation and pain following ocular surgery, indicating a broad market potential.

Eyenovia is considering the development of APP13007 in Optejet for the dry eye market, estimated to be around $3.6 billion in the United States. Management said it awaits approval before proceeding with the dry eye program, aiming to leverage the approved filing for strategic advantages.

With the approval, William Blair increased the risk-adjusted fair value from $5 to $7 per share, with an Outperform rating.

Price Action: EYEN shares are down 0.30% at $23.04 on the last check Tuesday.

Photo by Amanda Dalbjörn on Unsplash

Latest Ratings for EYEN

DateFirmActionFromTo
Apr 2021HC Wainwright & Co.MaintainsBuy
Oct 2020HC Wainwright & Co.MaintainsBuy
Oct 2020Roth CapitalMaintainsBuy
View More Analyst Ratings for EYEN

View the Latest Analyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.